Title | Type | SJR | H index | Total Docs. (2023) | Total Docs. (3years) | Total Refs. (2023) | Total Cites (3years) | Citable Docs. (3years) | Cites / Doc. (2years) | Ref. / Doc. (2023) | %Female (2023) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
81 | Cancer Innovation | journal | 0.389 Q4 | 4 | 56 | 20 | 3056 | 23 | 19 | 1.15 | 54.57 | 41.16 | |
80 | NanoWorld Journal | journal | 0.166 Q4 | 6 | 150 | 59 | 3074 | 51 | 56 | 0.56 | 20.49 | 13.43 | |
79 | Annals of Cancer Research and Therapy | journal | 0.192 Q4 | 7 | 8 | 80 | 232 | 28 | 80 | 0.41 | 29.00 | 34.04 | |
78 | Advances in Cancer Biology - Metastasis | journal | 0.376 Q4 | 8 | 34 | 73 | 3131 | 164 | 70 | 2.25 | 92.09 | 44.62 | |
77 | Journal of Immunotherapy and Precision Oncology | journal | 0.668 Q3 | 9 | 24 | 83 | 1050 | 117 | 63 | 1.85 | 43.75 | 37.40 | |
76 | World Cancer Research Journal | journal | 0.239 Q4 | 13 | 56 | 160 | 1987 | 156 | 157 | 1.05 | 35.48 | 44.44 | |
75 | Annual review of biomedical data science | journal | 3.034 Q1 | 22 | 22 | 56 | 2883 | 411 | 56 | 7.73 | 131.05 | 44.55 | |
74 | National Toxicology Program technical report series | journal | 0.111 Q4 | 22 | 2 | 5 | 185 | 1 | 5 | 0.00 | 92.50 | 0.00 | |
73 | Cancer Drug Resistance | journal | 1.035 Q2 | 24 | 47 | 210 | 5023 | 844 | 205 | 4.27 | 106.87 | 45.99 | |
72 | Blood cancer discovery | journal | 4.640 Q1 | 25 | 42 | 128 | 1802 | 959 | 125 | 8.13 | 42.90 | 35.32 | |
71 | Current Pathobiology Reports | journal | 0.446 Q4 | 33 | 0 | 27 | 0 | 75 | 27 | 3.71 | 0.00 | 0.00 | |
70 | JCO clinical cancer informatics | journal | 1.396 Q2 | 33 | 128 | 309 | 0 | 1160 | 288 | 2.44 | 0.00 | 44.66 | |
69 | JNCI Cancer Spectrum | journal | 2.101 Q1 | 33 | 98 | 330 | 3652 | 1201 | 297 | 3.30 | 37.27 | 51.13 | |
68 | JCO Global Oncology | journal | 1.138 Q2 | 39 | 157 | 563 | 2 | 1859 | 519 | 2.73 | 0.01 | 46.55 | |
67 | Journal of Experimental Therapeutics and Oncology | journal | 0.108 Q4 | 40 | 0 | 5 | 0 | 0 | 4 | 0.00 | 0.00 | 0.00 | |
66 | Current Hematologic Malignancy Reports | journal | 0.998 Q2 | 44 | 31 | 130 | 2271 | 402 | 130 | 2.83 | 73.26 | 46.74 | |
65 | Current Problems in Cancer | journal | 0.759 Q3 | 47 | 50 | 226 | 2582 | 551 | 216 | 2.48 | 51.64 | 51.07 | |
64 | JCO Precision Oncology | journal | 2.249 Q1 | 48 | 0 | 395 | 0 | 1632 | 356 | 4.46 | 0.00 | 0.00 | |
63 | Cancer genetics | journal | 0.530 Q3 | 52 | 46 | 226 | 1458 | 346 | 221 | 1.32 | 31.70 | 49.04 | |
62 | Critical Reviews in Oncogenesis | journal | 0.319 Q4 | 57 | 29 | 87 | 1311 | 72 | 69 | 0.60 | 45.21 | 46.67 | |
61 | Journal of Environmental Science and Health, Part C: Toxicology and Carcinogenesis | journal | 0.438 Q4 | 59 | 8 | 54 | 659 | 116 | 53 | 1.41 | 82.38 | 47.62 | |
60 | Nature Cancer | journal | 11.900 Q1 | 61 | 176 | 453 | 7513 | 5933 | 297 | 12.27 | 42.69 | 43.45 | |
59 | Clinical Lymphoma, Myeloma and Leukemia | journal | 0.548 Q3 | 65 | 160 | 1295 | 6531 | 1737 | 1261 | 1.13 | 40.82 | 43.46 | |
58 | Oncogenesis | journal | 1.855 Q1 | 67 | 55 | 243 | 2653 | 1386 | 242 | 5.54 | 48.24 | 46.04 | |
57 | Cancer Biotherapy and Radiopharmaceuticals | journal | 0.607 Q3 | 68 | 91 | 285 | 3180 | 871 | 281 | 2.79 | 34.95 | 41.63 | |
56 | Cancer cytopathology | journal | 0.991 Q2 | 68 | 107 | 375 | 2808 | 1003 | 253 | 2.53 | 26.24 | 46.36 | |
55 | Technology in Cancer Research and Treatment | journal | 0.609 Q3 | 72 | 230 | 815 | 11793 | 2100 | 809 | 2.51 | 51.27 | 44.59 | |
54 | Translational Oncology | journal | 1.263 Q2 | 72 | 231 | 831 | 11856 | 3891 | 812 | 4.53 | 51.32 | 41.85 | |
53 | Clinical Lung Cancer | journal | 1.263 Q2 | 74 | 137 | 530 | 4023 | 1756 | 487 | 3.23 | 29.36 | 37.07 | |
52 | Oncology Research | journal | 0.472 Q3 | 76 | 70 | 174 | 3993 | 354 | 165 | 1.40 | 57.04 | 45.85 | |
51 | Molecular Imaging and Biology | journal | 0.752 Q3 | 78 | 125 | 364 | 5604 | 999 | 346 | 2.79 | 44.83 | 38.09 | |
50 | Clinical Breast Cancer | journal | 0.942 Q2 | 80 | 165 | 503 | 6540 | 1521 | 480 | 3.01 | 39.64 | 50.25 | |
49 | Melanoma Research | journal | 0.633 Q3 | 80 | 69 | 249 | 2717 | 440 | 230 | 1.44 | 39.38 | 48.32 | |
48 | Genes and Cancer | journal | 0.559 Q3 | 81 | 6 | 29 | 402 | 54 | 26 | 1.67 | 67.00 | 58.97 | |
47 | Sub-Cellular Biochemistry | journal | 0.726 Q3 | 81 | 65 | 120 | 9603 | 452 | 1 | 3.01 | 147.74 | 0.00 | |
46 | Oncology | journal | 0.336 Q4 | 83 | 41 | 257 | 596 | 188 | 207 | 1.14 | 14.54 | 31.50 | |
45 | Stem Cell Reviews and Reports | journal | 1.190 Q2 | 87 | 203 | 486 | 16046 | 2279 | 439 | 4.48 | 79.04 | 44.03 | |
44 | European Journal of Cancer Prevention | journal | 0.665 Q3 | 88 | 77 | 236 | 3202 | 477 | 213 | 1.86 | 41.58 | 51.00 | |
43 | American Journal of Clinical Oncology: Cancer Clinical Trials | journal | 0.711 Q3 | 90 | 87 | 334 | 2755 | 645 | 309 | 1.55 | 31.67 | 39.06 | |
42 | Medical Oncology | journal | 0.763 Q3 | 90 | 359 | 520 | 23351 | 1600 | 500 | 3.02 | 65.04 | 40.77 | |
41 | Trends in Cancer | journal | 4.513 Q1 | 90 | 111 | 338 | 7747 | 3828 | 324 | 9.71 | 69.79 | 40.00 | |
40 | Cancer Investigation | journal | 0.604 Q3 | 93 | 83 | 247 | 3668 | 452 | 229 | 1.77 | 44.19 | 39.25 | |
39 | Journal of the National Cancer Institute. Monographs | journal | 1.319 Q2 | 95 | 27 | 58 | 747 | 184 | 55 | 2.19 | 27.67 | 68.20 | |
38 | Breast | journal | 1.688 Q1 | 98 | 127 | 518 | 4905 | 2659 | 484 | 5.42 | 38.62 | 52.73 | |
37 | Nuclear Medicine and Biology | journal | 0.658 Q3 | 98 | 42 | 210 | 1676 | 603 | 200 | 3.15 | 39.90 | 40.13 | |
36 | Tumor Biology | journal | 0.576 Q3 | 101 | 15 | 84 | 457 | 193 | 82 | 1.89 | 30.47 | 52.63 | |
35 | Anti-Cancer Drugs | journal | 0.476 Q3 | 102 | 143 | 526 | 4507 | 1045 | 525 | 1.89 | 31.52 | 44.60 | |
34 | Cancer journal (Sudbury, Mass.) | journal | 0.933 Q2 | 102 | 55 | 218 | 3810 | 493 | 200 | 2.51 | 69.27 | 38.30 | |
33 | Seminars in Radiation Oncology | journal | 1.038 Q2 | 103 | 46 | 134 | 3187 | 426 | 124 | 2.68 | 69.28 | 40.72 | |
32 | Current Opinion in Oncology | journal | 0.990 Q2 | 104 | 85 | 290 | 4473 | 919 | 267 | 2.68 | 52.62 | 44.00 |
Follow us on @ScimagoJR
Scimago Lab, Copyright 2007-2024. Data Source: Scopus®